314 related articles for article (PubMed ID: 30662441)
1. Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
Tatfi M; Hermine O; Suarez F
Front Immunol; 2018; 9():3060. PubMed ID: 30662441
[TBL] [Abstract][Full Text] [Related]
2. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
3. miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas.
Cao P; Zhang M; Wang L; Sai B; Tang J; Luo Z; Shuai C; Zhang L; Li Z; Wang Y; Li G; Xiang J
BMC Cancer; 2018 Dec; 18(1):1293. PubMed ID: 30594162
[TBL] [Abstract][Full Text] [Related]
4. Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells.
Hau PM; Deng W; Jia L; Yang J; Tsurumi T; Chiang AK; Huen MS; Tsao SW
J Virol; 2015 Jan; 89(1):652-68. PubMed ID: 25355892
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus Hijacks DNA Damage Response Transducers to Orchestrate Its Life Cycle.
Hau PM; Tsao SW
Viruses; 2017 Nov; 9(11):. PubMed ID: 29144413
[TBL] [Abstract][Full Text] [Related]
6. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
[TBL] [Abstract][Full Text] [Related]
7. Gene expression analysis in EBV-infected ataxia-telangiectasia cell lines by RNA-sequencing reveals protein synthesis defect and immune abnormalities.
Tatfi M; Perthame E; Hillion KH; Dillies MA; Menager H; Hermine O; Suarez F
Orphanet J Rare Dis; 2021 Jun; 16(1):288. PubMed ID: 34183044
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the latent-lytic switch in Epstein-Barr virus.
Kenney SC; Mertz JE
Semin Cancer Biol; 2014 Jun; 26():60-8. PubMed ID: 24457012
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-associated lymphoproliferative disorders.
Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; Roliński J
Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
[TBL] [Abstract][Full Text] [Related]
11. DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.
Wang'ondu R; Teal S; Park R; Heston L; Delecluse H; Miller G
PLoS One; 2015; 10(5):e0126088. PubMed ID: 25950714
[TBL] [Abstract][Full Text] [Related]
12. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
13. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency.
Bienemann K; Borkhardt A; Klapper W; Oschlies I
Histopathology; 2015 Nov; 67(5):607-16. PubMed ID: 25728094
[TBL] [Abstract][Full Text] [Related]
14. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
15. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
[TBL] [Abstract][Full Text] [Related]
16. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
17. In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications.
Gonzalez-Farre B; Rovira J; Martinez D; Valera A; Garcia-Herrera A; Marcos MA; Sole C; Roue G; Colomer D; Gonzalvo E; Ribera-Cortada I; Araya M; Lloreta J; Colomo L; Campo E; Lopez-Guillermo A; Martinez A
Mod Pathol; 2014 Dec; 27(12):1599-611. PubMed ID: 24762547
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
[TBL] [Abstract][Full Text] [Related]
19. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus (EBV) and lymphomagenesis.
Cesarman E
Front Biosci; 2002 Feb; 7():e58-65. PubMed ID: 11815280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
